Updated:
Corcept Therapeutics
Corcept Therapeutics, led by Joseph Belanoff, built a debt-free biotech around cortisol modulation, with Korlym generating over $400M in annual revenue.
Corcept Therapeutics
Corcept Therapeutics was founded in 1998 by Joseph Belanoff, Alan Schatzberg, and James G. Wilson, emerging from research on the glucocorticoid receptor and its role in psychiatric and metabolic disorders. The company's intellectual foundation rests on the work of Schatzberg, a Stanford psychiatrist whose studies linked excess cortisol to psychotic depression, providing the scientific rationale for Corcept's drug development program. Corcept's entire business revolves around Korlym (mifepristone), a cortisol receptor blocker approved by the FDA in 2012 for Cushing's syndrome patients who have failed surgery or are not surgical candidates. The company has since followed a patent-extension and label-expansion strategy, filing additional formulations and next-generation selective cortisol modulators, including relacorilant, now in Phase III trials for Cushing's syndrome and ovarian cancer. The geographic footprint remains overwhelmingly US-focused, with all commercial revenue tied to the American market and an internal specialty endocrinology sales force. The company reported $402 million in revenue for the fiscal year 2023, with approximately 300 employees spread across its Menlo Park headquarters and a commercial infrastructure serving roughly 3,500 active prescribers. In September 2024, Corcept announced that relacorilant met its primary endpoint in the GRACE Phase III trial for Cushing's syndrome, paving the way for an anticipated new drug application submission in 2025 (per the firm, September 2024). Corcept is structurally unusual in biotech: it has no debt, funds clinical development entirely from Korlym's commercial cash flows, and has never taken a strategic partner on its lead pipeline asset. This independence allows it to pursue a long, methodical label-expansion strategy without dilution pressure or a partner's portfolio priorities. The company has also defended its Korlym franchise aggressively through patent litigation against Teva and other generic challengers, reinforcing a revenue runway that supports its pipeline entirely internally.
General information
Firm type
Asset Manager
Year founded
1998
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Principals
Joseph K. Belanoff
Chief Executive Officer
Sector focus
Frequently asked questions
What is Corcept Therapeutics' core scientific focus?
Corcept targets the glucocorticoid receptor, specifically blocking cortisol activity associated with Cushing's syndrome and certain cancers. Its approved drug, Korlym, competes directly with ketoconazole and other off-label steroidogenesis inhibitors used by endocrinologists. The pipeline extends this mechanism into oncology via relacorilant, a selective cortisol modulator in late-stage trials.
How does Corcept fund its operations given it is a single-product company?
Corcept is self-funding. Korlym generated $402 million in net revenue in 2023, and the company carries no long-term debt. All pipeline development, including the Phase III program for relacorilant, is funded from commercial cash flows rather than equity raises or partnership upfronts.
Which companies compete directly with Corcept's Korlym franchise?
The primary competitive threat is generic mifepristone, which Corcept has delayed through patent litigation against Teva, Sun Pharma, and others. In the broader Cushing's market, off-label use of ketoconazole, metyrapone, and Novartis's Signifor represents clinical competition. Relacorilant, if approved, would face competition from Strongbridge's Recorlev and Recordati's Isturisa in the non-generic segment.
Who controls investment and strategic decisions at Corcept?
Joseph Belanoff, CEO and co-founder, has led the company since 1998 and exercises significant control over R&D prioritization and capital allocation. The board includes Robert B. Stein, a former Roche executive, and several long-tenured directors who have overseen the company's transition from clinical-stage to profitable commercial entity.
What is the commercial durability of Korlym given its age?
Korlym's patent estate extends into the 2030s through formulation patents, method-of-use protections, and regulatory exclusivity periods. The company's litigation strategy has successfully blocked multiple generic challengers, and the small addressable patient population — roughly 7,000 identified Cushing's patients in the US — has discouraged aggressive generic entry.
Does Corcept have any exposure beyond US markets?
No. All revenue is US-derived, with no ex-US commercial infrastructure. Pipeline trials have been conducted in the US and Europe, but the company has no announced plans for international commercialization and has not sought a marketing authorization outside the FDA.
What happens to Corcept if relacorilant fails to gain FDA approval?
The company would revert to a single-product profile entirely dependent on Korlym's commercial tail. Management would still have a cash-positive business generating approximately $400 million annually, but absent a pipeline catalyst, the equity story would shift to capital return, M&A, or licensing-in assets to redeploy accumulated cash.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: